137 related articles for article (PubMed ID: 31097519)
1. Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.
Luengo-Fernandez R; Penz E; Dobson M; Psallidas I; Nunn AJ; Maskell NA; Rahman NM
Eur Respir J; 2019 Aug; 54(2):. PubMed ID: 31097519
[TBL] [Abstract][Full Text] [Related]
2. Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
Rahman NM; Maskell NA; West A; Teoh R; Arnold A; Mackinlay C; Peckham D; Davies CW; Ali N; Kinnear W; Bentley A; Kahan BC; Wrightson JM; Davies HE; Hooper CE; Lee YC; Hedley EL; Crosthwaite N; Choo L; Helm EJ; Gleeson FV; Nunn AJ; Davies RJ
N Engl J Med; 2011 Aug; 365(6):518-26. PubMed ID: 21830966
[TBL] [Abstract][Full Text] [Related]
3. New strategies to manage complicated pleural effusions.
Safiyeh M; Huang D
Crit Care; 2012 May; 16(3):312. PubMed ID: 22621656
[TBL] [Abstract][Full Text] [Related]
4. Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients.
Kanellakis NI; Wrightson JM; Hallifax R; Bedawi EO; Mercer R; Hassan M; Asciak R; Hedley E; Dobson M; Dong T; Psallidas I; Rahman NM
BMJ Open Respir Res; 2019; 6(1):e000440. PubMed ID: 31673364
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial.
Livingston MH; Mahant S; Connolly B; MacLusky I; Laberge S; Giglia L; Yang C; Roberts A; Shawyer A; Brindle M; Parsons S; Stoian C; Walton JM; Thorpe KE; Chen Y; Zuo F; Mamdani M; Chan C; Loong D; Isaranuwatchai W; Ratjen F; Cohen E
JAMA Pediatr; 2020 Apr; 174(4):332-340. PubMed ID: 32011642
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural agents for pleural infection: fibrinolytics and beyond.
Rahman NM
Curr Opin Pulm Med; 2012 Jul; 18(4):326-32. PubMed ID: 22487944
[TBL] [Abstract][Full Text] [Related]
7. Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery.
Piccolo F; Pitman N; Bhatnagar R; Popowicz N; Smith NA; Brockway B; Nickels R; Burke AJ; Wong CA; McCartney R; Choo-Kang B; Blyth KG; Maskell NA; Lee YC
Ann Am Thorac Soc; 2014 Nov; 11(9):1419-25. PubMed ID: 25296241
[TBL] [Abstract][Full Text] [Related]
8. Modified regimen intrapleural alteplase with pulmozyme in pleural infection management: a tertiary teaching hospital experience.
Cheong XK; Ban AY; Ng BH; Nik Abeed NN; Nik Ismail NA; Nik Fuad NF; Syed Zakaria SZ; Ghan SL; Abdul Hamid MF
BMC Pulm Med; 2022 May; 22(1):199. PubMed ID: 35581627
[TBL] [Abstract][Full Text] [Related]
9. Predictive Variables for Failure in Administration of Intrapleural Tissue Plasminogen Activator/Deoxyribonuclease in Patients With Complicated Parapneumonic Effusions/Empyema.
Khemasuwan D; Sorensen J; Griffin DC
Chest; 2018 Sep; 154(3):550-556. PubMed ID: 29425674
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of intrapleural fibrinolytic therapy and dosing strategies used for complicated pleural effusions.
Baumgartner L; Huang E; Sherman D
Pulm Pharmacol Ther; 2022 Oct; 76():102146. PubMed ID: 35868601
[TBL] [Abstract][Full Text] [Related]
11. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
[TBL] [Abstract][Full Text] [Related]
12. Alteplase Dose Assessment for Pleural infection Therapy (ADAPT) Study-2: Use of 2.5 mg alteplase as a starting intrapleural dose.
Popowicz N; Ip H; Lau EPM; Piccolo F; Dootson K; Yeoh C; Phu WY; Brown R; West A; Ahmed L; Lee YCG
Respirology; 2022 Jul; 27(7):510-516. PubMed ID: 35441458
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.
Ruggeri M; Basile M; Zini A; Mangiafico S; Agostoni EC; Lobotesis K; Saver J; Coretti S; Drago C; Cicchetti A
J Med Econ; 2018 Sep; 21(9):902-911. PubMed ID: 29882711
[TBL] [Abstract][Full Text] [Related]
15. Dose De-escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection. The Alteplase Dose Assessment for Pleural Infection Therapy Project.
Popowicz N; Bintcliffe O; De Fonseka D; Blyth KG; Smith NA; Piccolo F; Martin G; Wong D; Edey A; Maskell N; Lee YCG
Ann Am Thorac Soc; 2017 Jun; 14(6):929-936. PubMed ID: 28324671
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
[TBL] [Abstract][Full Text] [Related]
17. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective.
Sinclair SE; Frighetto L; Loewen PS; Sunderji R; Teal P; Fagan SC; Marra CA
Pharmacoeconomics; 2001; 19(9):927-36. PubMed ID: 11700779
[TBL] [Abstract][Full Text] [Related]
18. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection. A Single-Center Experience.
Majid A; Kheir F; Folch A; Fernandez-Bussy S; Chatterji S; Maskey A; Fashjian M; Cheng G; Ochoa S; Alape D; Folch E
Ann Am Thorac Soc; 2016 Sep; 13(9):1512-8. PubMed ID: 27333122
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece.
Maniadakis N; Kaitelidou D; Siskou O; Spinthouri M; Liaropoulos L; Fragoulakis B; Hatzikou M; Alexopoulosi D
Hellenic J Cardiol; 2005; 46(3):212-21. PubMed ID: 15981557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
